Nail Your Sales Interview with the 30/60/90 Day Sales Plan
If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.

Now you can nail your interview with the 30 60 90 Day Sales Plan template with Audio Coaching. This simple tool will help you knock the socks off your interviewer and bury your competition.

To get the details: Click Here

[Close Window]
Medical Sales Jobs Websites - the best Medical Sales Jobs | Laboratory Sales Jobs | Medical Device Sales Jobs

Posts on ‘November 30th, 2009’

FDA Grants Orphan Drug Designation for THREE,4-DAP for LEMS

Nov 30th, 2009
by admin.
No comments yet

NOVATO, Calif., Nov. Thirty (HSMN NewsFeed) — BioMarin Laboratory Inc. (Nasdaq: BMRN ) announced today that the Food and Drug Administration (FDA) has granted orphan drug designation for THREE,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the ra…
Biopharmaceuticals, FDA
BioMarin Lab, 3,4-diaminopyridine, Lambert Eaton Myasthenic Syndrome

Depomed Files Patent Infringement Lawsuit Against Lupin Limited

Nov 30th, 2009
by admin.
No comments yet

MENLO PARK, Calif.–(HSMN NewsFeed)–Depomed, Inc. (Nasdaq:DEPO ) today announced that it has filed a lawsuit in the United States District Court for the Northern District of California against Lupin Limited and its wholly-owned subsidiary, Lupin Pharmaceu…
Biopharmaceuticals, Generics, Litigation, FDA
Depomed, Lupin Pharmaceuticals, GLUMETZA, metformin

sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America

Nov 30th, 2009
by admin.
No comments yet

BRIDGEWATER, N.J., Nov. 30 (HSMN NewsFeed) — sanofi-aventis U.S. announced today the signing of an exclusive licensing agreement with Intelliject, Inc. for a novel epinephrine auto injector for the emergency treatment of allergic reactions (anaphylaxis)…
Devices, Biopharmaceuticals, Drug Delivery, Licensing
sanofi-aventis, Intelliject, epinephrine, injector

Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer’s Disease

Nov 30th, 2009
by admin.
No comments yet

WAYNE, N.J. and CHICAGO, Nov. 30 (HSMN NewsFeed) — Today at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Bayer HealthCare Pharmaceuticals Inc. announced the enrollment of the first patient in an in…
Biopharmaceuticals, Devices, Radiology, Neurology
Bayer HealthCare, florbetaben, PET imaging, amyloid, Alzheimer’s